Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Ocean Biomedical, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
10/06/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "FIRST AMENDMENT TO COMMON STOCK PURCHASE AGREEMENT, DATED",
"Ocean Biomedical Announces Loan Commitment from Largest"
10/02/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "SIDE LETTER"
08/16/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/16/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/04/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/03/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/24/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
07/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
07/06/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
06/08/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "AMENDMENT TO LOAN AGREEMENT, DATED JUNE 2, 2023",
"OMNIBUS AMENDMENT TO LOAN AGREEMENTS, DATED JUNE 2, 2023"
06/01/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
05/26/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT"
05/24/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/16/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "[FORM OF SENIOR SECURED CONVERTIBLE NOTE] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE ...",
"[FORM OF WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER ...",
"GUARANTY This GUARANTY, dated as of May 16, 2023 , is made by each of the undersigned , in favor of Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, in its capacity as collateral agent for the “Buyers” party to the Securities Purchase Agreement . W I T N E S S E T H : WHEREAS, Ocean Biomedical, Inc., a company organized under the laws of Delaware, with offices located at 55 Claverick St. Rm. 325, Providence, RI 02903 and each party listed as a “Buyer” on the Schedule of Buyers attached thereto are parties to the Securities Purchase Agreement, dated as of May 15, 2023 , pursuant to which the Company shall be required to sell, and the Buyers shall purchase or have the right to purchase, the “Notes” issued pursuant thereto ; WHEREAS, the Securities Purchase Agreement require...",
"W I T N E S S E T H : WHEREAS, the Company is party to that certain Securities Purchase Agreement, dated as of May 15, 2023, by and among the Company and each party listed as a “Buyer” on the Schedule of Buyers attached thereto , pursuant to which the Company shall be required to sell, and the Buyers shall purchase or have the right to purchase, the “Notes” issued pursuant thereto ; WHEREAS, certain Grantors from time to time may execute and deliver one or more guarantees in form and substance acceptable to and in favor of the Collateral Agent, for the ratable benefit of itself and the Noteholders, with respect to the Company’ s obligations under the Securities Purchase Agreement, the Notes and the other Transaction Documents",
"RECITALS",
"RECITALS",
"Ocean Biomedical, Inc. Enters into a $25 Million Convertible Note Facility"
04/21/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
03/31/2023 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "OCEAN BIOMEDICAL, INC. AND SUBSIDIARIES INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Financial Statements Consolidated Balance Sheets F-3 Consolidated Statements of Operations F-4 Consolidated Statements of Stockholders’ Equity F-5 Consolidated Statements of Cash Flows F-6 Notes to Consolidated Financial Statements F-7 - F-25 F- 1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the shareholders and the Board of Directors of Ocean Biomedical, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Ocean Biomedical, Inc. and subsidiaries as of December 31, 2022 and 2021, the related consolidated statements of operations, stockholders’ deficit, and cash flows...",
"OCEAN BIOMEDICAL’ S MANAGEMENT’ S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS",
"UNAUDITED PRO FORMA COMBINED CONsolidated FINANCIAL INFORMATION Introduction The following unaudited pro forma combined financial information presents the combination of the financial information of Aesther Healthcare Acquisition Corp. and Ocean Biomedical, Inc. adjusted to give effect to a completed transaction on February 14, 2023 , whereas, AHAC consummated the Agreement and Plan of Merger dated August 31, 2022 as amended on December 5, 2022 . On the Closing Date, AHAC Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of AHAC merged with and into Ocean Biomedical, Inc., with Ocean Biomedical, Inc., continuing as the surviving entity and a wholly-owned subsidiary of AHAC . In connection with the closing of the Business Combination , AHAC changed its name from “Aesther H..."
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/17/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
02/24/2023 SC 13D Aesther Healthcare Sponsor, LLC reports a 19.9% stake in Ocean Biomedical, Inc.
02/24/2023 SC 13D Poseidon Bio, LLC reports a 63.7% stake in Ocean Biomedical, Inc.
02/14/2023 SC 13G First Trust Capital Management L.P. reports a 5.4% stake in Aesther Healthcare Acquisition Corp.
02/14/2023 SC 13G Lighthouse Investment Partners, LLC reports a 6.4% stake in Aesther Healthcare Acquisition Corp.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 425 Form 425 - Prospectuses and communications, business combinations:
02/13/2023 8-K Quarterly results
02/13/2023 425 Form 425 - Prospectuses and communications, business combinations:
02/13/2023 8-K Quarterly results
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 425 Form 425 - Prospectuses and communications, business combinations:
02/10/2023 8-K Quarterly results
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy